Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $10 price target.
Wedbush analyst Robert Driscoll reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and maintains $10 price target.